ALLURION TECHNOLOGIES INC - ALUR STOCK NEWS

Allurion Technologies (NYSE: ALUR) reported its Q4 and full-year 2024 financial results. Q4 revenue was $5.6 million with full-year revenue reaching $32.1 million. The company faced challenges with Q4 gross profit at $2.5 million (45% margin), down from $6.4 million (78% margin) in Q4 2023.

Key developments include:

• Resumed sales in France on February 12, 2025
• Positive topline results from AUDACITY FDA trial
• Initial data showing promising results combining Allurion Program with low-dose GLP-1s
• Launch of next-generation Allurion Balloon with smaller capsule size

The company reduced Q4 2024 operating expenses by 39% year-over-year to $19.6 million, including $3.8 million in restructuring charges. For 2025, Allurion projects revenue of approximately $30 million and plans to cut operating expenses by roughly 50% compared to 2024.

Allurion Technologies (NYSE: ALUR) has revealed promising initial results from combining the Allurion Program with low-dose GLP-1 therapy. The study involved 52 patients who received the Allurion Balloon and started on 0.25mg semaglutide, gradually increased to 1.0mg over 6 months.

Key findings after 8 months include:

• 20.3% average total body weight loss
• 15% increase in lean body mass (from 59.6% to 68.5%)
• 100% patient adherence to GLP-1 medication

This combination approach addresses common challenges with standalone GLP-1 therapy, which typically shows 40% reduction in lean mass and high discontinuation rates (30% in first month, 58% before reaching meaningful health benefits). The study used lower semaglutide doses (max 1.0mg) compared to typical 2.4mg dosing, resulting in fewer side effects and better adherence.

Allurion Technologies (NYSE: ALUR), an anti-obesity focused company, has scheduled its fourth quarter 2024 financial results announcement for March 26, 2025. The company will host a conference call and webcast at 8:30 AM ET on the same day to discuss the results and provide a business update.

Investors can access the conference call via phone at (888) 330-3417 (domestic) or +1 646 960 0804 (international) using Conference ID 1905455. A live audio webcast will be available in the Events section of Allurion's Investor Relations website. A replay will be accessible by phone using Access Code 1905455 and through the archived webcast on the company's IR website.

Allurion Technologies (NYSE: ALUR) has received two new U.S. patent notifications from the USPTO for its next-generation weight loss device. The patents, scheduled to issue on March 11, 2025, cover an enhanced valve for balloon filling and an innovative balloon opening mechanism, providing protection through April 2043.

The company's patent portfolio now includes 22 U.S. patents and 64 global patents. The Allurion Program combines their swallowable, procedure-less gastric balloon with the Allurion Virtual Care Suite, featuring a Mobile App, Connected Scale, and Iris AI Platform for healthcare providers.

Clinical results show patients typically lose 10-15% of their total body weight, with some studies demonstrating increased muscle mass. The company plans to conduct new clinical trials combining the Allurion Balloon with GLP-1 therapy.

Allurion Technologies (NYSE: ALUR), a company focused on ending obesity, has announced its participation in two major upcoming investor conferences. Dr. Shantanu Gaur, Founder and CEO, will present at the 45th Annual TD Cowen Healthcare Conference in Boston on March 3, 2025, at 9:10 a.m. ET, where he will also conduct one-on-one investor meetings.

Additionally, Dr. Gaur will host individual investor meetings at the 37th Annual Roth Conference in Dana Point, California, from March 16-18, 2025. Investors can access the presentation webcast through the Events & Presentations section of Allurion's investor relations website.

Allurion Technologies (NYSE: ALUR) has successfully closed its previously announced financing round, raising approximately $6.1 million through multiple transactions. The company completed a registered direct offering of 900,000 common stock shares at $5.23 per share, along with warrants for 1,800,000 additional shares. Additionally, a concurrent private placement with Leavitt Equity Partners included 267,686 shares and warrants for 535,372 shares at the same price.

The warrants have an exercise price of $5.23 per share and will become exercisable immediately following stockholder approval, with a five-year expiration term. Roth Capital Partners served as the exclusive placement agent for both transactions. The company plans to use the proceeds to fund clinical trials exploring the combination of the Allurion Balloon with GLP-1 therapy, focusing on muscle mass and long-term GLP-1 adherence, as well as for working capital and general corporate purposes.

Allurion Technologies (NYSE: ALUR) has announced a financing deal to raise approximately $6.1 million in gross proceeds through a combination of offerings. The company will sell 900,000 shares of common stock at $5.23 per share in a registered direct offering and issue warrants for 1,800,000 additional shares in a concurrent private placement.

Additionally, the company entered into a subscription agreement with Leavitt Equity Partners for 267,686 shares and warrants for 535,372 shares at the same price point. The warrants have an exercise price of $5.23 per share and will be exercisable upon stockholder approval, expiring five years after approval.

The proceeds will fund Allurion's clinical pipeline testing the combined effects of the Allurion Balloon and GLP-1 therapy on muscle mass and long-term GLP-1 adherence, working capital, and general corporate purposes. The closing is expected around February 20, 2025.

Allurion Technologies (NYSE: ALUR) has announced plans to initiate a clinical study combining the Allurion Balloon with GLP-1 agonists to treat obesity. The study aims to demonstrate improved long-term tolerability and adherence to GLP-1 therapy using lower doses.

Current data shows that 30% of patients discontinue GLP-1 therapy within the first month, and 58% stop before achieving meaningful health benefits due to side effects, dose escalation requirements, and cost. Previous research, published in Obesity Surgery, demonstrated enhanced weight loss and co-morbidity resolution at four months when combining the Allurion Balloon with oral semaglutide compared to balloon therapy alone.

Allurion Technologies (NYSE: ALUR) has received clearance from ANSM, the French regulatory authority, to resume sales of the Allurion Balloon in France, historically their top-performing market representing approximately 15% of revenue. The company is also exploring clinical trials in French clinics to study the combination of the Allurion Balloon with GLP-1s, aiming to address muscle mass loss during obesity treatment.

In France, approximately 47% of the population has excess weight, with 17% classified as obese. While GLP-1 therapies have shown to reduce lean mass by about 40% of total weight lost, previous studies of the Allurion Balloon combined with Virtual Care Suite demonstrated that patients can lose weight while maintaining or increasing muscle mass. In one study of 571 patients, subjects gained 5.6% in lean body mass while losing 14% of total body weight over four months. Another study with 167 patients showed a 15.7% weight reduction with no muscle mass loss.